Navigation Links
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Date:8/19/2007

tient's level of M protein.

Kosan anticipates that the pivotal TIME-1 trial will begin later in 2007 or in early 2008. TIME-1 will be an open-label, randomized, multi-center trial that is designed to enroll over 450 patients with disease relapse following a single prior course of treatment (first-relapse). The trial is designed to compare two groups: patients treated with bortezomib plus tanespimycin and patients treated with bortezomib alone. Tanespimycin will be administered at a dose of 340 mg/m2 and all patients will receive standard doses of bortezomib (1.3 mg/m2). TIME-1 is designed with a primary endpoint of progression-free survival. Kosan anticipates providing more background on the TIME-1 trial design upon initiation.

About Tanespimycin

Tanespimycin has been shown to induce apoptosis of drug-sensitive and drug-resistant multiple myeloma cell lines. Tanespimycin also inhibits expression of various cell surface cytokines, such as IGF-1R and IL-6R, that are involved in growth, survival and drug resistance of multiple myeloma cells. Destabilizing client proteins with tanespimycin while blocking their degradation with bortezomib promotes the accumulation of cytotoxic proteins, leading to cell death.

Kosan reported data from a Phase 1b trial of tanespimycin in combination with bortezomib at the 2007 annual meeting of the American Society for Clinical Oncology (ASCO) on 56 patients enrolled in 7 dose cohorts (100-340 mg/m2 of tanespimycin; 0.7-1.3 mg/m2 of bortezomib; tanespimycin administered via 1-hour infusion following the bortezomib dose 2 times per week every 2 weeks out of 3 weeks). Of these 56 patients, all had received multiple prior chemotherapy regimens (median of 4) and 67% had received bone marrow transplants.

In those patients who received tanespimycin across the range of doses tested and a dose of 1.0 or 1.3 mg/m2 of bortezomib, the overall response rate including complete, partial and minimal responses was, as previou
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 /PRNewswire/ ... , the largest, independent manufacturer of phosgene and ... , today announced that it has acquired Framochem ... based in Hungary . ... product offerings and creates one of the world,s ...
(Date:8/1/2014)... LAKE FOREST, Ill. , Aug. 1, 2014 ... private equity firm focused exclusively on the healthcare ... Inc. ("Vesta") to The Lubrizol Corporation ("Lubrizol"). Lubrizol, ... company that produces and supplies technologies to customers ... Terms of the transaction were not disclosed. ...
(Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
Breaking Medicine Technology:VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... Jan. 18 ,Exelixis, Inc. (Nasdaq: EXEL ) ... exercise its option to license XL784 for further,development ... meet its primary endpoint in a phase 2 ... in one subgroup were encouraging,Exelixis believes that the ...
... Specialty Pharmacy, one,of the largest privately owned national ... an agreement with Genzyme Corporation to,administer their 2008 ... the world,s largest biotechnology companies dedicated to products,and ... transplant, and oncology., Diplomat will be the ...
Cached Medicine Technology:GSK Does Not Option XL784 for Further Development 2GSK Does Not Option XL784 for Further Development 3Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program 2
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) lauds ... Peter Welch (D-VT), for their latest actions to ... of 2014, which improves telemedicine coverage in Medicare. ... healthcare access and affordability using telecommunications technology," said ... cost-saving provisions are critical to improve telehealth coverage ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... Taking menstrual cycle into account when booking exam may cut ... (HealthDay News) -- Using a blood test to pinpoint the ... menstrual cycles could reduce the need for repeat scans, U.S. ... MRI scans during the follicular phase (days 3 to14) of ...
... simple blood test corresponding to the follicular phase (days ... optimal scheduling of breast MRI exams in premenopausal women ... repeat scans and non-diagnostic tests patients experience and providing ... to a study published in the December issue of ...
... Virginia Commonwealth University Massey Cancer Center and VCU Institute ... may play a pivotal role in two processes that ... metastasis. Scientists hope the finding could lead to an ... this gene resulting in inhibition of cancer growth. ...
... alcohol dependence problems drink significantly more than do younger adults ... The findings suggest that older problem drinkers may have developed ... than younger abusers to achieve the effects they seek. ... 60 who have alcohol dependence drink more than 40 alcoholic ...
... , NORTHBROOK, Ill., Nov. 20 ... one of the fastest growing cosmetic skin care providers ... injections, Zerona(TM) laser treatments and SmartLipo(TM) body contouring at ... cosmetics industry, new innovations and technologies are constantly being ...
... Mallika Chopra, healthy living expert and founder and CEO ... products in the US, are teaming up to help Americans ... with advice from Chopra, to be posted today on Intent.com. ... the stress or foreboding that typically comes with this time ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:Researchers identify role of gene in tumor development, growth and progression 2Health News:Older problem drinkers use more alcohol than do their younger counterparts 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 3Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Control of thumb motion can be difficult ... for persons with spinal cord injuries and ... to cerebral palsy or other motor or ... the thumb for control and coordination. Soft ...
... ThumWrap Splints offer support without the restriction ... mild pain or strain due to repetitive ... the rigid or the flexible stay to ... Washable and breathable, the ThumWrap Splint is ...
Medicine Products: